Abstract
A successful potency assay for a cell therapy product (CTP) used in the treatment of ischemic conditions should quantitatively measure relevant biological properties that predict therapeutic activity. This is especially challenging because of numerous degrees of complexity stemming from factors that include a multifactorial complex mechanism of action, cell source, inherent cell characteristics, culture method, administration mode and the in vivo conditions to which the cells are exposed. The expected biological function of a CTP encompasses complex interactions that range from a biochemical, metabolic or immunological activity to structural replacement of damaged tissue or organ. Therefore, the requirements for full characterization of the active substance with respect to biological function could be taxing. Moreover, the specific mechanism of action is often difficult to pinpoint to a specific molecular entity; rather, it is more dependent on the functionality of the cellular components acting in a in a multifactorial fashion. In the case of ischemic conditions, the cell therapy mechanism of action can vary from angiogenesis, vasculogenesis and arteriogenesis that may activate different pathways and clinical outcomes. The CTP...Continue Reading
References
May 4, 1999·The Journal of Clinical Investigation·J M Isner, T Asahara
Jan 24, 2004·Circulation Research·T KinnairdS E Epstein
Sep 4, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Paolo MadedduCesare Peschle
Dec 17, 2004·Pharmacological Reviews·Ann HoebenErnst A De Bruijn
Apr 28, 2006·Statistics in Medicine·UNKNOWN Committee for Medicinal Products for Human UseUNKNOWN Committee for Release for Consultation
Oct 21, 2006·British Journal of Haematology·Yael PoratNaphtali Savion
Nov 1, 2006·Circulation·Atsuhiko KawamotoDouglas W Losordo
Mar 27, 2007·Clinical and Experimental Nephrology·Masamichi EguchiTakayuki Asahara
Jun 15, 2007·Circulation·Douglas W LosordoTimothy D Henry
Jan 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Jochen TillmannsPiero Anversa
Apr 3, 2008·Asian Cardiovascular & Thoracic Annals·Kitipan V AromVibul Jotisakulratana
May 21, 2008·European Journal of Heart Failure·Zhuo SunRen-Ke Li
Aug 6, 2008·Journal of Leukocyte Biology·Melany C van OostromImo E Hoefer
Aug 8, 2008·Acta Biochimica Et Biophysica Sinica·Weijun Cai, Wolfgang Schaper
Aug 30, 2008·Journal of Molecular and Cellular Cardiology·Kentaro JujoDouglas W Losordo
Jan 27, 2009·Journal of Cellular Physiology·Rosendo EstradaEugenia Wang
Feb 11, 2010·Microvascular Research·Jörn TongersDouglas W Losordo
Aug 23, 2011·The International Journal of Developmental Biology·Anca-Maria CimpeanMarius Raica
Jun 13, 2012·Cytotherapy·Nicholas LehmanJuliana Woda
Jul 31, 2012·Stem Cells and Development·Hong-Chao ZhangZi-Kuan Guo
Oct 4, 2012·Developmental Biology·Domenico Ribatti, Enrico Crivellato
Nov 30, 2012·Circulation. Cardiovascular Interventions·Douglas W LosordoUNKNOWN Autologous CD34+ Cell Therapy for Critical Limb Ischemia Investigators
Jan 12, 2013·Circulation·Jae Choon RyuJonathan R Lindner
Citations
Jul 8, 2016·Stem Cells Translational Medicine·Carl G SimonAnne L Plant
Jul 31, 2020·Stem Cell Research & Therapy·Pei-Hsun SungHon-Kan Yip
Dec 16, 2020·ACS Biomaterials Science & Engineering·Deepika AroraCarl G Simon
Nov 12, 2017·Trends in Biotechnology·Ross A MarkleinSteven R Bauer
Sep 1, 2021·Stem Cell Reviews and Reports·Lidia Gómez-CidFrancisco Fernández-Avilés